Completed PHASE2 INTERVENTIONAL NCT00984464

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

A Phase 2 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Sponsor: Oncolytics Biotech

Conditions Metastatic Melanoma

Interventions Carboplatin Paclitaxel REOLYSIN

Updated 6 times since 2017 Last updated: Apr 8, 2015 Started: Sep 30, 2009 Primary completion: Feb 28, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00984464, this PHASE2 trial focuses on Metastatic Melanoma and remains completed. Sponsored by Oncolytics Biotech, it has been updated 6 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oncolytics Biotech
University of Texas

Data source: Oncolytics Biotech

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Antonio, United States